Structural insights into SARS-CoV-2 proteins
The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …
effort of the global scientific community to unravel different aspects of the disease in a short …
Structural characterization of SARS-CoV-2: where we are, and where we need to be
G Mariano, RJ Farthing, SLM Lale-Farjat… - Frontiers in molecular …, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread in
humans in almost every country, causing the disease COVID-19. Since the start of the …
humans in almost every country, causing the disease COVID-19. Since the start of the …
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
J Osipiuk, SA Azizi, S Dvorkin, M Endres… - Nature …, 2021 - nature.com
The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases …
2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases …
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
There is an urgent need for antiviral agents that treat severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs …
coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs …
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug
development. In this study, we present an antiviral screening strategy involving a novel in …
development. In this study, we present an antiviral screening strategy involving a novel in …
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
V Mody, J Ho, S Wills, A Mawri, L Lawson… - Communications …, 2021 - nature.com
Emerging outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection is a major threat to public health. The morbidity is increasing due to lack of SARS …
infection is a major threat to public health. The morbidity is increasing due to lack of SARS …
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing
coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments …
coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments …
Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the pathogen
that causes the disease COVID-19, produces replicase polyproteins 1a and 1ab that …
that causes the disease COVID-19, produces replicase polyproteins 1a and 1ab that …
X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the pathogen
that causes COVID-19, produces polyproteins 1a and 1ab that contain, respectively, 11 or …
that causes COVID-19, produces polyproteins 1a and 1ab that contain, respectively, 11 or …